The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
Wardley
A M
AM
Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
Jayson
G C
GC
Goldsmith
D J
DJ
Venning
M C
MC
Ackrill
P
P
Scarffe
J H
JH
D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000150:complications / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin